Last reviewed · How we verify

NCT04662333

Adjunctive Benefit of Xenograft Plus a Membrane During Sinus Crestal Approach

Status unknown NA Last updated 10 December 2020
What this trial tests

NA trial testing Transcrestal approach for sinus lift in Edentulous Jaw in 36 participants. Status unknown.

Timeline
1 October 2020
Primary endpoint
1 March 2023
1 March 2023

Quick facts

Lead sponsorUniversity of Siena
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment36
Start date1 October 2020
Primary completion1 March 2023
Estimated completion1 March 2023
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Siena

Who can join

18 and older, any sex, with Edentulous Jaw. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients in need for implant-supported restoration in maxillary posterior sites with insufficient residual bone height will be randomly allocated to two different arms. Crestal sinus lift with simultaneous implant placement will be performed in both groups. Control group: crestal sinus lift with no adjunctive biomaterial; Test group: crestal sinus lift associated with xenogenic bone graft and collagen membrane; Six months after implant placement, implants will be loaded with definitive screw-retained prostheses. Six months later, patients will be recalled for clinical and radiographic assessment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Edentulous Jaw

Currently open trials in the same condition.

Other University of Siena trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04662333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing